

免疫治療研究部 論文(2014 年)

【英語論文】

原著論文

1. Iizuka A, Komiyama M, Oshita C, Kume A, Ashizawa T, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K, Akiyama Y. Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. *Immunol Lett.* 2014;159(1-2):15-22.
2. Ashizawa T, Akiyama Y, Miyata H, Iizuka A, Komiyama M, Kume A, Omiya M, Sugino T, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K. Effect of the STAT3 inhibitor STX-0119 on the proliferation of temozolomide-resistant glioblastoma cell line. *Int J Oncol.* 2014;45(1):411-418.
3. Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, Iizuka A, Kume A, Sugino T, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K. YKL-40 downregulation is key factor to overcome temozolomide resistance in a glioblastoma cell line. *Oncol Rep.* 2014 ;32(1):159-166.
4. Akiyama Y, Komiyama M, Miyata H, Yagoto M, Ashizawa T, Iizuka A, Oshita C, Kume A, Nogami M, Ito I, Watanabe R, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K. Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients. *Oncol Rep.* 2014;31(4):1683-1690.
5. Akiyama Y, Komiyama M, Miyata H, Nogami M, Ozawa K, Oshita C, Kume A, Ashizawa T, Sakura N, Mochizuki T, Yamaguchi K. The identification of affinity peptide ligands specific to the variable region of human antibodies. *Biomed Res.* 2014;35(2):105-16.